Related Experiment Video

Updated: Mar 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Does ruxolitinib prolong the survival of patients with myelofibrosis?

Francisco Cervantes1, Arturo Pereira2

  • 1Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and.

Blood
|December 30, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K

Related Experiment Videos

Last Updated: Mar 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

British journal of haematology·2026

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

International journal of molecular sciences·2026

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026

Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.

British journal of haematology·2026

Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis.

Lupus science & medicine·2025

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.

Blood·2025

Molecular Consequences and Targeting of PPM1D Overexpression in Myeloproliferative Neoplasms.

Blood·2026

Ambient oxygen disrupts amino acid homeostasis and impairs human hematopoietic stem and progenitor cell engraftment.

Blood·2026

Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.

Blood·2026

KPNA2-Mediated MYC Nuclear Import Enhances CAR-T Cell Memory and Potentiates Antitumor Efficacy.

Blood·2026

How I Identify and Diagnose Carriers of Hemophilia and Women and Girls with Hemophilia.

Blood·2026

The origins of rare glycosylphosphatidylinositol-deficient cells in normal and immune-mediated hematopoiesis.

Blood·2026

Diabetes Status and the Association Between a Coronary Artery Disease Polygenic Risk Score and Incident Coronary Artery Disease in an Iranian Prospective Cohort.

Medical journal of the Islamic Republic of Iran·2026

AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation.

Frontiers in pharmacology·2026

FOXM1 Drives Subtype-Specific Dysregulation of Prognostic miRNAs in Breast Cancer Cells.

Journal of clinical practice and research·2026

Evaluation of Preoperative Factors Associated with Early Postoperative Neurological Outcome in the Treatment of Metastatic Spinal Tumors.

Indian journal of orthopaedics·2026

Molecular mechanisms and targeted therapeutic strategies for glycolytic reprogramming in osteosarcoma.

Genes & diseases·2026

Molecular and microenvironmental networks driving tumor dormancy: pathological mechanisms and emerging clinical strategies.

Frontiers in medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us